Arimidex (anastrozole), a once-daily oral aromatase inhibitor for postmenopausal hormone receptor-positive breast cancer, is available from M Care as either the AstraZeneca brand or a licensed generic 1 mg tablet, quoted against your tender specification.
Arimidex (anastrozole), originated by AstraZeneca, is a third-generation non-steroidal aromatase inhibitor that blocks peripheral oestrogen synthesis in postmenopausal women, taken as a single 1 mg tablet once a day rather than infused or injected. M Care Exports is a merchant exporter: we source Arimidex and licensed generic anastrozole tablets through Indian distribution and manufacturing channels and dispatch on quote, not from our own manufacturing.
Anastrozole exporter and bulk supplier from India.
For hospital oncology pharmacy, wholesaler and MoH tender orders, M Care quotes anastrozole 1 mg tablets against buyer specification: originator Arimidex or a licensed generic line, pack size and the destination market's own import documentation, drawn from licensed WHO-GMP manufacturer lines on the M Care roster. Because adjuvant anastrozole is typically a five-year daily course, we confirm the buyer's repeat-order cadence and pack-appearance continuity needs before dispatch, then align CTD/eCTD or country-specific dossier paperwork to the destination regulator's requirements.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Third-generation non-steroidal aromatase inhibitor; endocrine antineoplastic, sourced and documented for export.
Anastrozole is a third-generation, non-steroidal aromatase inhibitor. It works by blocking the aromatase enzyme that converts androgens to oestrogen in peripheral tissue, cutting circulating oestrogen levels in postmenopausal women whose breast tumour is hormone receptor-positive and therefore growth-dependent on that oestrogen supply. It is an oral, non-injectable therapy, dosed as a single 1 mg tablet once daily, with no reconstitution or infusion step. Arimidex's FDA-labelled indications cover adjuvant treatment of hormone receptor-positive early breast cancer, first-line treatment of hormone receptor-positive or hormone-receptor-unknown advanced or metastatic breast cancer, and second-line treatment after disease progression on tamoxifen, all restricted to postmenopausal women; it is not effective in premenopausal women and has not been studied in men. The UK and EU-harmonised SmPC additionally licenses anastrozole for primary prevention of breast cancer in postmenopausal women at moderate or high risk, a use not carried on the US label, so buyers should check which indication set their own destination-country labelling supports before a tender quote is finalised.
Active ingredient
Anastrozole. Third-generation non-steroidal aromatase inhibitor; endocrine antineoplastic.
Forms and strengths
1 mg film-coated tablet.
Indications
Anastrozole is a non-steroidal aromatase inhibitor that blocks peripheral oestrogen synthesis in postmenopausal women, indicated for hormone receptor-positive breast cancer in adjuvant, first-line advanced and second-line settings. Supplied from Indian channels as originator Arimidex or licensed generic tablets to regulated and semi-regulated export markets.
Administration
Oral. Film-coated tablet.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for anastrozole are hospital oncology and breast-unit pharmacists managing adjuvant endocrine therapy over a five-year course, national and regional MoH tender desks running breast-cancer treatment protocols, licensed pharmaceutical wholesalers and importers stocking oncology and endocrine-therapy ranges, and NGO or foundation procurement programmes supporting breast-cancer treatment access in markets where local registration is in place.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on anastrozole.
Anastrozole is confirmed-postmenopausal-only dosing: 1 mg once daily, with no renal or hepatic dose adjustment required in mild-to-moderate impairment per the label, but menopausal status should be biochemically confirmed before a premenopausal or perimenopausal patient starts therapy, since anastrozole does not suppress ovarian oestrogen production. The adherence-critical point for a five-year adjuvant course is continuity: a switch between the Arimidex brand and a generic anastrozole tablet, or between two generic manufacturers, changes tablet appearance and packaging, which measurably affects adherence in elderly patients managing a long-running regimen, so dispensing continuity is worth flagging to a tender desk alongside price. Bone mineral density falls on aromatase inhibitor therapy, so baseline and periodic DEXA scanning, calcium and vitamin D supplementation, and bisphosphonate co-therapy where indicated are standard supportive care. Serum cholesterol should also be monitored, and arthralgia and hot flushes are common class effects worth counselling patients on before they discontinue therapy prematurely. As an oral tablet, anastrozole needs no cold-chain handling.
The documentation pack a regulator actually asks for.
Anastrozole tablets are a room-temperature oral solid dosage form, stored at 20 to 25 degrees C per the FDA label, so they travel on standard ambient, GDP-compliant logistics rather than the validated cold-chain lanes M Care runs for biologics and infused cytotoxics; what buyers need instead is batch-level certificate of analysis, CDSCO export documentation and CTD/eCTD-format dossier support where the destination regulator requires local registration. Anastrozole has sat on the WHO Model List of Essential Medicines since 2015 (TRS 994), on the complementary list under section 8.2.4, Hormones and antihormones, listed with a square-box notation that treats the wider L02BG aromatase-inhibitor class, including letrozole, as therapeutic alternatives, which is worth factoring into formulary-substitution policy rather than treating the two agents as automatically interchangeable on a tender line. On the brand-versus-generic question, this is a straightforward small-molecule oral tablet: licensed generic anastrozole tablets are separately approved and marketed in the US, UK and EU alongside AstraZeneca's originator Arimidex, so brand and generic are genuinely interchangeable on a standard bioequivalence basis, unlike some narrow-therapeutic-index oncology products. M Care does not manufacture anastrozole itself and holds no WHO-GMP or WHO-PQ certification in its own name; every batch exported carries its manufacturing partner's own certification.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside anastrozole.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for anastrozole.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Anastrozole supply, the specific questions.
Is Arimidex the same medicine as anastrozole?
Yes. Anastrozole is the non-proprietary name and Arimidex is AstraZeneca's originator brand. Licensed generic anastrozole tablets are separately approved and marketed in the US, UK and EU, so buyers can specify either the brand or a generic line against a tender.
What is anastrozole licensed to treat?
In the US, adjuvant treatment of hormone receptor-positive early breast cancer, first-line treatment of hormone receptor-positive or hormone-receptor-unknown advanced or metastatic breast cancer, and second-line treatment after tamoxifen failure, all in postmenopausal women. The UK and EU label additionally covers primary prevention of breast cancer in postmenopausal women at moderate or high risk. Check destination-country labelling for the exact indication set.
Can M Care supply anastrozole for our tender or hospital order?
Yes. Tell us your strength and pack requirement, brand-or-generic preference and destination market, and we quote Arimidex or a licensed generic anastrozole line against your specification, drawn from licensed WHO-GMP manufacturer lines on the M Care roster.
Does anastrozole need cold-chain shipping?
No. Anastrozole is a film-coated tablet stored at controlled room temperature, 20 to 25 degrees C, and moves on standard ambient, GDP-compliant logistics rather than the validated cold-chain lanes we use for biologics and many infused cytotoxics.
Is anastrozole on the WHO Essential Medicines List?
Yes. Anastrozole has been on the WHO Model List of Essential Medicines since 2015, on the complementary list under hormones and antihormones, listed with a square-box notation alongside the wider aromatase-inhibitor class, including letrozole, as therapeutic alternatives.
Are brand and generic anastrozole interchangeable?
Broadly yes. Anastrozole is a standard oral small-molecule tablet, and licensed generic versions are separately approved on ordinary bioequivalence grounds in the US, UK and EU alongside AstraZeneca's Arimidex. For long adjuvant courses we still flag any brand-to-generic switch to the dispensing pharmacy, since a change in tablet appearance can affect patient adherence over a five-year regimen.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-13.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.